The European Commission Approved QDENGA (TAK-003) for Use in Individuals Four Years of Age and Olderi QDENGA Becomes the Only Dengue Vaccine Approved in the EU for Use in Individuals Regardless of Previous
Describing and analysing the prevalence, clinical characteristics, risk factors, and outcomes of COVID-19 pneumothorax patients in the intensive care unit.
Researchers demonstrated clinical features and infectivity of the currently dominant SARS-CoV-2 variant of concern Omicron, compared to Delta, the previously dominant VOC.
/PRNewswire/ UCB, a global biopharmaceutical company, announced today it is presenting results from across its portfolio in generalized myasthenia gravis.